Kornimate/medical-research-clean huggingface dataset:
a study to assess clinical gingivitis and microbiome following the use of multiple oral hygiene products

Conditions: Dental Plaque; Dental Gingivitis

Summary: this study assessed the efficacy of an oral hygiene regimen relative to a standard marketed toothpaste and manual toothbrush.


Eligibility criteria:
inclusion criteria: * give written informed consent prior to their participation; * be 18 to 65 years of age at the time of enrollment; * agree not to participate in any other oral/dental product studies; * agree to delay any elective dentistry (including a dental prophylaxis); * agree to refrain from the use of any non-study oral care products (including floss and mouthrinse) during the course of the study; * agree to return for the scheduled visits and follow study procedures; * be in good general health as determined by the investigator/designee based on a review of the health history/update for participation in the study; * have more than 10 bleeding sites at visits 1-3 * consistency of bleeding site number at baseline may be considered; * have a minimum of 18 natural teeth with facial and lingual scorable surfaces; and * refrain from performing any oral hygiene or consuming anything by mouth (except a small amount of water) at least 4 hours prior to their appointment. exclusion criteria: * teeth that are grossly carious, fully crowned, extensively restored and have heavy dental calculus * antibiotic, anti-inflammatory or anti-coagulant therapy within two weeks of to the baseline exam * medical conditions that the investigator considers significant and that may compromise the evaluation of study results * currently participating in any other clinical trial * participated in a clinical trial for plaque/gingivitis within the previous 30 days * pregnant or lactating * orthodontic appliances or removable partial dentures * soft or hard tissue tumor of the oral cavity * advanced periodontal disease * history of hepatitis, diabetes, or other communicable diseases * history of rheumatic fever, heart murmur, mitral valve prolapse or other conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures * history of significant adverse effects following the use of oral hygiene products such as toothpaste * oral pathoses that could interfere with compliance and/or examinations or that need treatment.
lymphatic system reflux after lymphatic operation

Conditions: Lymphedema

Summary: this study aimed to determine the impact on outcomes when recipient veins with reflux were used for lva for the treatment of unilateral lower limb lymphedema.

the use of recipient veins with reflux for lymphaticovenous anastomosis (lva) is discouraged because of the common belief that it may lead to venous-lymphatic reflux (vlr), a phenomenon in which venous blood is refluxed into the lymphatic lumen after anastomosis, which can lower the long-term patency rate. however, this concept has yet to be validated.

Eligibility criteria:
inclusion criteria: * this study including patients diagnosed with lymphatic-related diseases at kaohsiung chang gung memorial hospital from october 1, 2015, to december 31, 2022. * patients who underwent lva for unilateral lower-limb lymphedema. exclusion criteria: * patients under the age of 20. * patients lost to follow-up or with incomplete data.
a trial of local anaesthesia versus local anaesthesia and conscious sedation for hernioplasty

Conditions: Inguinal Hernia; Anesthesia, Local; Conscious Sedation

Summary: the aim of this rct is to compare patient outcomes of inguinal hernioplasty under local anaesthesia alone versus local anaesthesia and conscious sedation specific study objectives are to determine the effect of conscious sedation on: (i) patient satisfaction (ii) postoperative pain (iii) time to discharge (iv) intraoperative complications (v) postoperative functional status (vi) short-term postoperative complications (vii) long-term postoperative complications


Eligibility criteria:
inclusion criteria: * reducible inguinal hernia exclusion criteria: * renal, hepatic, respiratory, cardiovascular, neurologic or psychiatric disease * body mass index \ 30 kg/m2 * recurrent inguinal hernias * bilateral inguinal hernias * large inguinoscrotal hernias * incarcerated hernia * allergies to local anaesthetic and sedative agents * pregnancy * lactation * chronic pain syndromes * anxiety disorders * marijuana use * long term use of opioid or sedative agents

Keywords: inguinal hernia, local anesthesia randomized clinical trial hernioplasty
tumor-specific t cells in lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: non-small cell lung cancer is characterized by aggressive growth and treatment resistance. new approaches include immunotherapeutic strategies but spontaneous immune responses against tumor antigens remain unclear. the aim of this study is to characterize localization and frequencies of spontaneously induced memory t cells specific for a panel of tumor-associated antigens in peripheral blood and bone marrow of non-small cell lung cancer patients.


Eligibility criteria:
inclusion criteria: * patients with histology proven non-small cell lung cancer or a lesion suspicious of non-small cell lung cancer (lung cancer group) * healthy donors (control group) * written informed consent exclusion criteria: * autoimmune disease * patients receiving immunomodulatory drugs, e.g. tacrolimus * prior malignancy * pregnancy
(pioneer) study to evaluate efficacy and safety of avapritinib (blu-285), a selective kit mutation-targeted tyrosine kinase inhibitor, versus placebo in patients with indolent systemic mastocytosis

Conditions: Indolent Systemic Mastocytosis

Summary: this is a phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (bsc) with placebo + bsc in patients with indolent systemic mastocytosis (ism) whose symptoms are not adequately controlled by bsc. the study will be conducted in 3 parts. all patients will receive treatment with avapritinib during part 3 including those rolling over from the placebo group.


Eligibility criteria:
key inclusion criteria: * 1. patient must have sm, confirmed by central pathology review of bm biopsy, and central review of b- and c-findings by who diagnostic criteria. * 2. patient must have moderate-to-severe symptoms based on minimum mean total symptom score (tss) of the ism symptom assessment form (ism-saf) over the 14-day eligibility screening period. * 3. patient must have failed to achieve adequate symptom control for 1 or more baseline symptoms. * 4. for patients receiving corticosteroids, the dose must be ≤ 20 mg/d prednisone or equivalent, and the dose must be stable for ≥ 14 days. * 5. patient must have an eastern cooperative oncology group (ecog) performance status (ps) of 0 to 2. key exclusion criteria: * 1. patient has been diagnosed with any of the following who sm subclassifications: cutaneous mastocytosis only, smoldering sm, sm with associated hematologic neoplasm, aggressive sm, mast cell leukemia, or mast cell sarcoma. * 2. patient must not have received prior treatment with avapritinib. * 3. patient must not have had any cytoreductive therapy including but not limited to masitinib and midostaurin, or investigational agent for \< 14 days or 5 half-lives of the drug (whichever is longer), and for cladribine, interferon alpha, pegylated interferon, or antibody therapy \< 28 days or 5 half-lives of the drug (whichever is longer), before beginning the 14-day ism-saf eligibility tss assessment. * 4. patient must not have received radiotherapy or psoralen and ultraviolet a (puva) therapy \< 14 days before beginning the 14-day ism-saf eligibility tss assessment. * 5. patient must not have received any hematopoietic growth factor the preceding 14 days before beginning the 14-day ism-saf eligibility tss assessment. * 6. patient must not have a qt interval corrected using fridericia's formula (qtcf) of \> 480 msec.
semi-quantitative cough strength score (scss)

Conditions: Mechanical Ventilation

Summary: cough strength score will give true prediction of extubation outcome

head trauma patients were evaluated for readiness to be weaned off mechanical ventilation. if they had completed an spontaneous breathing trial (sbt) before extubation. to measure semiquantitative cough strength score (scss), the investigator will put the patients at 30° to 45°, measure scss, first. the investigator enhance the patient to cough with as much effort as, when the investigator disconnect the ventilator. the cough strength was scored from 0 to 5 as follows: 0 = no cough on command, 1 = audible movement of air through the endotracheal tube but no audible cough, 2 = weakly (barely) audible cough, 3 = clearly audible cough, 4 = stronger cough and 5 = multiple sequential strong coughs.

Eligibility criteria:
inclusion criteria: * the study included 80 adult male and female patients' their ages between 18-65 years admitted to trauma icu with head trauma, on mechanical ventilation more than 24 hours and was ready to be weaned off from mechanical ventilation after successful spontaneous breathing trial and glasgow coma scale (gcs) score \> 8 before extubation exclusion criteria: • patients who had undergone tracheostomy before extubation, gcs ≤ 8, chest trauma (ribs fracture and lung contusion) and patients with chronic chest disease (chronic obstructive pulmonary disease, tuberculosis and cancer lung) were excluded from the study.
digital impression in neonates

Conditions: Unilateral Complete Cleft Lip and Palate

Summary: the goal of this \[clinical trial\] is to \[explore the attitudes of guardians with different educational background regarding the technique of impression registration as well as the compliance to using feeding appliances \] in \[neonates\]. researchers will compare \[conventional impression technique to digital impression\]


Eligibility criteria:
inclusion criteria: * patients with unilateral complete cleft lip and palate * neonates exclusion criteria: * infants and children * bilateral cleft lip and palatal * incomplete cleft lip
effects of hmos on the faecal microbiota and on host metabolism in obese children

Conditions: Obesity

Summary: the study is a randomised, placebo-controlled, double-blind, parallel study in obese children. a total of 75 obese children in the age 5 to 10 years, enrolled in a childhood obesity treatment program, will be included. the participating children will be randomised into one of three groups consuming either hmo (two groups) or placebo (one group). the primary objective of the study is to establish the effects of hmos on the faecal microbiota in children. secondary objectives are to evaluate safety of hmo supplementation in children and the effect on gastrointestinal symptoms (tolerance), bowel habits, metabolic profile and body composition in obese children.


Eligibility criteria:
inclusion criteria: 1. informed, written consent by the child's representative(s) and informed verbal assent by the child 2. age ≥5 and \<11 years at visit 0 3. bmi sds of ≥ 2.3 4. enrolment in the childhood obesity treatment program at the children's obesity clinic 5. ability and willingness to understand and comply with the study procedures 6. the child's representative(s) need(s) to read, speak and understand danish exclusion criteria: 1. participation in another clinical intervention study one month prior to the screening visit and throughout the study. 2. any gastrointestinal disease(s) that may cause symptoms or may interfere with the trial outcome, as judged by the investigator. 3. other severe disease(s) such as malignancy, kidney disease or neurological disease, as judged by the investigator. 4. psychiatric disease, as judged by the investigator. 5. use of probiotic supplements (yoghurt allowed) 3 months prior to screening and throughout the study. 6. consumption of antibiotic drugs 3 months prior to screening and throughout the study. 7. consumption on a regular basis of medication that might interfere with symptom evaluation (as judged by the investigator) 2 weeks prior to screening and throughout the study. 8. lack of suitability for participation in the study for any reason as judged by the investigator.
effect of preoperative diclofenac potassium on articaine buccal infitration success

Conditions: Pulpitis - Irreversible; Anesthesia, Local

Summary: the purpose of this study is to assess the effect of preoperative diclofenac potassium (50 mg cataflam) on the anesthetic success of buccal infiltration with 4% articaine with epinephrine 1:200,000 in mandibular molars with symptomatic irreversible pulpitis.

this study aims to evaluate the effectiveness of preoperative administration of diclofenac potassium (50 mg cataflam) compared to placebo, one hour before treatment, on the anesthetic success of buccal infiltration with 4% articaine with epinephrine 1:200,000 in mandibular molars with symptomatic irreversible pulpitis. patients with moderate-to-severe pre-operative pain are selected. full medical and dental history will be obtained from all patients treated during this study by the operator. clinical diagnosis of symptomatic irreversible pulpitis is to be confirmed. the primary outcome is success of buccal infiltration using articaine.the secondary outcomes are pain on injection. patients will be recruited from the outpatient clinic of endodontics at the faculty of oral and dental medicine, cairo university.

Eligibility criteria:
inclusion criteria: * patients with active pain (moderate-to-severe) in mandibular molars. * patients with prolonged response to cold testing and electric pulp tester. * patient with the ability to understand and use pain scales. * patient with vital coronal pulp tissue on access. * patient who accept to enroll to the study. exclusion criteria: * patients' allergies or any other contraindication to diclofenac potassium or articaine. * pregnant and lactating females. * patients having pain medication in the last 6 hours. * patient has more than one symptomatic mandibular tooth in the same quadrant. * patients with periradicular pathosis and/or radiolucency other than widened periodontal ligaments. * patients with active peptic ulcer and gastrointestinal disorders. * patients with history of bleeding problems or anticoagulant use within the last month.

Keywords: pulpitis, irreversible pulpitis, hot tooth cataflam, diclofenac potassium, preoperative, premedication, analgesic local anesthesia, articaine, buccal infiltration
cerebro spinal fluid collection (csf)

Conditions: Alzheimer Disease; Dementia With Lewy Bodies; Frontotemporal Dementia; Parkinson's Disease Dementia; Multiple System Atrophy

Summary: cognitive neurodegenerative diseases are a major public health issue. at present, the diagnosis of certainty is still based on anatomopathological analyses. even if the diagnostic tools available to clinicians have made it possible to improve probabilistic diagnosis during the patient's lifetime, there are still too many diagnostic errors and sub-diagnostic in this field. the arrival of biomarkers has made it possible to reduce these diagnostic errors, which were of the order of 25 to 30%. this high error rate is due to different parameters. these diseases are numerous and often present common symptoms due to the fact that common brain structures are affected. these diseases evolve progressively over several years and their early diagnosis, when the symptoms are discrete, makes them even more difficult to diagnose at this stage. in addition, co-morbidities are common in the elderly, further complicating the diagnosis of these diseases. at present, the only cerebrospinal fluid (csf) biomarkers that are routinely used for the biological diagnosis of neurodegenerative cognitive pathologies are those specific to alzheimer's disease: aβ42, aβ40, tau-total and phospho-tau. these biomarkers represent an almost indispensable tool in the diagnosis of dementia. it is therefore important to determine whether alzheimer's biomarkers can be disrupted in other neurodegenerative cognitive pathologies, but also to find biomarkers specific to these different pathologies by facilitating the implementation of clinical studies which will thus make it possible to improve their diagnosis.


Eligibility criteria:
inclusion criteria: * patients with lumbar puncture (lp) * patients with accurate clinical diagnosis exclusion criteria: * patients who do not have a lumbar puncture * patients for whom no accurate diagnostic information is available

Keywords: csf library database of patients with cognitive disorders
parent-based treatment for pediatric overweight

Conditions: Overweight; Obesity

Summary: the purpose of this study is to determine whether a parent/guardian intervention for adolescent overweight/obesity more effective than a nutritional counseling education curriculum for reducing body mass index z-score (bmi z-score) and related outcomes.

rates of pediatric overweight (po) among americans are increasing and associated with significant psychological, social, quality of life, and health related outcomes. because of the broad mental and physical health implications of po and the difficulty in sustaining weight loss as an adult, it is of interest to find successful methods of weight loss and/or prevention of weight gain for obese children and adolescents. the family unit is a logical and empirically supported point of intervention for po. interventions on this level have shown good long term efficacy in young children, but there is very little research on adolescent family intervention. within the eating disorder literature, there is growing support for the efficacy of family-based interventions (fbi) for adolescents. given its trans-developmental applicability, focus on family as the unit of intervention, and utility in creating a healthy eating environment, fbi is a logical candidate for adaptation to intervention for po and intervention for at-risk for overweight youth (fbi-po). the core of the current project is to test the feasibility and efficacy of an adapted fbi manual for adolescent overweight and at-risk for overweight in an outpatient eating and weight disorders clinic and compare this modality to a minimal nutritional educational control (nec) condition.

Eligibility criteria:
inclusion criteria: * ages 13-17 * male and female * living with at least one parent or guardian who is willing to participate in treatment * a bmi percentile \>85% for gender and age (e.g., overweight or at risk for overweight) exclusion criteria: * current psychotic illness * current alcohol/drug dependence * active suicidality * eating disorders (e.g., binge eating disorder) * history of bariatric surgery * medication associated with significant weight changes (e.g., antipsychotics) * serious medical or physical conditions resulting in significant weight changes (e.g., pregnancy, genetic disorders). * complications of obesity that contraindicate moderate physical activity (e.g. orthopedic disorders)

Keywords: overweight obesity adolescents family therapy
anterior spinal canal reconstruction and fusion surgery for treating degenerative cervical kyphosis with stenosis

Conditions: Degenerative Cervical Kyphosis With Stenosis

Summary: degenerative cervical kyphosis with stenosis (dcks) is a common cervical spine degenerative disease, causing pain, numbness, and weakness of limbs, which seriously affect the quality of life of the patient. surgery is an effective way to treat this condition, however, the best surgical procedure is still controversial. anterior spinal canal reconstruction and fusion surgery (acrf) is a new surgical procedure that previously proposed by our team, it combines the advantages of both the conventional anterior and posterior approach. the purpose of this study is to evaluate the safety and effectiveness of acrf surgery for treating dcks. a multicenter prospective randomized controlled trial was designed. eligible patients will be randomly divided into three groups, including the acrf group, the conventional anterior surgery group, and the conventional posterior surgery group. demographic data, surgery information, and follow-up results will be collected and compared between groups.


Eligibility criteria:
inclusion criteria: * patients are diagnosed with degenerative cervical kyphosis with stenosis * patients aged between 30 and 70 years * patients meet the indications for surgery * patients submitted written informed consent exclusion criteria: * tumor, infection, or trauma of the cervical spine * severe cervical kyphosis that greater than 50° * severe ossification of the posterior longitudinal ligament of the cervical spine * patients with ankylosing spondylitis * previous surgery of the cervical spine
reducing arrhythmia in dialysis by adjusting the rx electrolytes/ultrafiltration, study b

Conditions: End Stage Renal Disease

Summary: the purpose of this study is to test the feasibility of trials that change the dialysis ultrafiltration rate (ufr) by limiting the maximum rate and to estimate the extent to which limiting the ultrafiltration rate reduces the risk of abnormal heart rhythms in people with kidney failure who are being treated with chronic hemodialysis.

within four weeks of consent, subjects will have an implantable loop recorder (ilr) (medtronic linq) device implanted. subjects will be given a transmitter/charger and a patient care assistant which they will be required to keep for the duration of their participation in the study. ilr tracings will be uploaded automatically and reviewed by the study team for the occurrence of clinically significant arrhythmia. following ilr implantation, subjects will alternate between weekly periods in which the ultrafiltration rate can be unlimited or in which the ultrafiltration rate is limited to ≤10ml/kg/hour.

Eligibility criteria:
inclusion criteria: * maintenance hemodialysis therapy for end-stage renal disease * age 18-85 years (subjects between 18-40 years old will be required to have at least one of the following: history of congestive failure, diabetes, coronary or peripheral vascular disease, or arrhythmia) * \>30 days since dialysis initiation * ability to provide informed consent * interdialytic weight gain necessitating an uf rate of ≥13ml/kg/hour of dialysis to achieve the target post-dialysis weight in at least half of the dialysis sessions (≥6 sessions) in the month prior to enrollment exclusion criteria: * expected survival \<6 months-to allow trial completion * renal transplant, transfer to home or peritoneal dialysis, or to non-study hemodialysis facility anticipated within 6 months * prisoners or cognitive disability preventing informed consent * pregnancy. a pregnancy test will be required for women of child bearing potential prior to enrollment. a pregnancy test will not be required for women past the age of child-bearing potential \>55 years old, women with a history of surgical sterilization, or for women \<55 years of age who have not had a menses within the past 12 months * skin condition, immune dysfunction, history of multiple infections or other condition which increases risk of local infection with ilr placement * bleeding disorder or anti-coagulation that cannot be reversed for ilr placement * existing pacemaker, implantable monitor or defibrillator which precludes device placement * chronic, persistent af (defined as the presence of persistent af on all available ekgs at time of recent screening)

Keywords: arrythmia hemodialysis